Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from AbbVie.

Advances In™ Hematology: Toward Harmonization of Pathology and Oncology to Improve Patient Outcomes in AML, CLL, and MM

Release Date: July 30, 2021
Expiration Date: July 30, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the diagnostic testing and treatment-response monitoring in hematologic malignancies, with a forward-looking perspective on how testing approaches might impact clinical practice. The essentials of cytogenetic and molecular testing, risk stratification, and treatment response monitoring will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AbbVie.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, pathologists, and other health care professionals interested in the diagnosis, treatment, and management of hematologic malignancies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the evolving role of cytogenetic and molecular testing in clinical decision-making for hematologic malignancies
  • Identify guideline-based recommendations for molecular testing in hematologic malignancies
  • Review the available data on current and emerging targeted therapies in the treatment of patients with hematologic malignancies
  • Utilize testing approaches to stratify risk, individualize treatment, and monitor treatment response for hematologic malignancies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Irene Ghobrial, MD
Irene Ghobrial, MD
Professor of Medicine
Director of the Center for Prevention of Progression
Director of the Clinical Investigator Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: GlaxoSmithKline, Sanofi, Janssen Pharmaceuticals, Takeda Pharmaceutical Company, Celgene Corporation, Karyopharm Therapeutics, AbbVie, GNS Healthcare, Cellectar Biosciences, Medscape, Genentech/F. Hoffman-La Roche, Adaptive Biotechnologies, Bristol Myers Squibb, Aptitude Medical Systems, Curio Biotech, Oncopeptides.

Nitin Jain, MD
Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Pharmacyclics, AbbVie, Genentech, Bristol Myers Squibb, Pfizer, ADC Therapeutics, Seattle Genetics, Incyte Corporation, Celgene Corporation, AstraZeneca, Servier Pharmaceuticals, Cellectis, Verastem Oncology, Adaptive Biotechnologies, Precision Biosciences; Consultant: Pharmacyclics, AbbVie, Genentech, AstraZeneca, Verastem Oncology, Pfizer, Servier Pharmaceuticals, Adaptive Biotechnologies, Janssen Pharmaceuticals, Precision Biosciences.

Keith Pratz, MD
Keith Pratz, MD
Director, Leukemia Program
Associate Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Research Support: AbbVie, Astellas, Agios, Millennium; Consultant: AbbVie, Agios, Astellas, BMS, Novartis.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By